Tildacerfont does not have a Marketing Authorisation for use in the United Kingdom and is not routinely available on the National Health Service. Tildacerfront is still in early development and is being studied for use in the treatment of patients with classic congenital adrenal hyperplasia. Once the trials with the product are complete, the drug manufacturer will be able to apply for a Marketing Authorisation.
Most new medicines are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal or highly specialised technologies programmes which make recommendations for the NHS on whether treatments represent an effective use of NHS resources. NHS commissioners are legally required to fund treatments recommended by NICE. If the manufacturer seeks a Marketing Authorisation for Tildacerfont, it will be considered through the established topic selection process to determine whether it should be assessed by NICE.
If Tildacerfont receives a Marketing Authorisation, funding decisions will be the responsibility of NHS commissioners, taking into account the available evidence and any relevant NICE recommendations.